Multiple Myeloma Research and Treatments

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma

This study analyzes whole-genome sequencing data from multiple myeloma patients to show that the timing of genetic events, not just their presence, affects clinical outcomes.

B-cell-Specific Wwox Deletion Promotes Plasmablastic Tumor Development and Pro-Inflammatory Signatures in a Myeloma Mouse Model

This study shows that deleting Wwox in B cells accelerates tumor development and inflammation in a myeloma mouse model.

Utilizing Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma High-Risk Subgroups

The paper identifies novel immunotherapeutic targets in multiple myeloma high-risk subgroups using genomic data integration and validation.

A Comprehensive Targeted Panel of 295 Genes: Unveiling Key Disease Initiating and Transformative Biomarkers in MultipleMyeloma

This study develops a 295-gene targeted sequencing panel and an AI model to identify disease-initiating and transformative biomarkers in multiple myeloma.

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma.

This study identifies biallelic CD38 loss as a mechanism of resistance to anti-CD38 antibodies in multiple myeloma, with specific mutations affecting antibody efficacy.

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma

This study uses longitudinal multi-omic profiling to identify immune escape mechanisms and predictors of response in multiple myeloma.

Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradation

This study identifies a SLAMF1-derived peptide, P7N4, that induces apoptosis in multiple myeloma cells by degrading IRF4, enhancing chemotherapy efficacy and showing minimal toxicity to healthy cells.

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple Myeloma

This paper develops a monobody-drug conjugate targeting mutant RAS in multiple myeloma, showing improved anti-tumor effects and safety in vitro and in vivo.

Hallmarks of tumor-experienced T cells are absent in multiple myeloma patients from diagnosis through maintenance therapy

The paper profiles CD8+ T cells in multiple myeloma patients to assess tumor reactivity and exhaustion, finding no evidence of tumor-experienced T cells with hallmark exhaustion or activation features.

CCR1 inhibition sensitizes multiple myeloma cells toglucocorticoid therapy

This study shows that inhibiting CCR1 enhances the effectiveness of glucocorticoid therapy in multiple myeloma by reversing resistance mechanisms.

Novel Pan-ALDH Inhibitor KS100 Effectively Targets ALDH+/CD138- Stem-like Cells to Overcome Relapse in Multiple Myeloma

This study identifies KS100, a pan-ALDH inhibitor, as effective in reducing ALDH expression and viability of multiple myeloma cells, particularly ALDH+/CD138- stem-like cells, potentially overcoming relapse.

Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine Resistant Multiple Myeloma

This study identifies translational reprogramming via mTOR activation as a mechanism of omacetaxine resistance in multiple myeloma and suggests combination therapy with mTOR inhibitors.

Genotypic identification of polyclonal plasma cells in plasma cell dyscrasias shows an aberrant single-cell phenotype with clinical implications

The paper identifies polyclonal plasma cells in plasma cell dyscrasias using single-cell RNAseq and shows their pro-inflammatory status and clinical relevance through a derived signature.

High WEE1 expression is independently linked to poor survival in multiple myeloma

This study identifies high WEE1 expression as a prognostic marker in multiple myeloma, showing it is independently linked to poor survival and associated with dysregulated P53 pathways.

Toll-like receptor-1 (TLR-1) activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin

This study shows that TLR1 activation reduces immunoglobulin free light chain production in multiple myeloma cells, both alone and with bortezomib, and this effect is influenced by the bone marrow microenvironment.

High cholesterol increases myeloma tumour burden and promotes resistance to bortezomib

This study shows high cholesterol increases myeloma tumour burden and promotes resistance to bortezomib by elevating resistin levels in bone marrow.

Tunneling Nanotubes Between Bone Marrow Stromal Cells Support Transmitophagy and Resistance to Apoptosis in Myeloma

The paper shows myeloma cells transfer dysfunctional mitochondria to BMSCs via tunneling nanotubes, enabling transmitophagy and resistance to apoptosis under OGD.

Disrupting USP39 deubiquitinase Function Impairs the Survival and Migration of Multiple Myeloma Cells through ZEB1 Degradation

This study identifies USP39 as a critical survival and migration factor in multiple myeloma cells, showing that its disruption leads to ZEB1 degradation and reduced tumor growth.

Machine Learning Models for Predicting Multiple Myeloma Staging and MGUS Progression Using Gene Expression Data

This study develops ML models to predict multiple myeloma staging and MGUS progression using gene expression data, achieving AUC values above 0.8 with ElasticNet and other algorithms.

Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

This study maps epigenetic and transcriptional changes in myeloma progression from precursor to advanced stages, identifying key transcription factors involved in disease development.

Stage-specific gene ratios highlight genes and mechanisms related to presymptomatic and symptomatic Multiple Myeloma

The paper identifies stage-specific genes and pathways in Multiple Myeloma using monotonic expressed genes (MEGs) and gene pair ratios, showing their potential as biomarkers for disease progression.

Germline and somatic genetic effects on gene expression and outcome in patients with Multiple Myeloma

This study identifies germline and somatic genetic effects on gene expression and patient outcomes in Multiple Myeloma using matched genotype and expression data from 607 patients.

Inhibition of FOXM1 synergizes with BCL2 inhibitor Venetoclax in killing non-t(11;14) multiple myeloma cells via repressing MYC pathway

This paper shows that combining FOXM1 inhibitor NB73 with Venetoclax kills non-t(11;14) multiple myeloma cells by blocking the MYC pathway.

Selective killing of plasma cell clones using splice-switching oligonucleotides targeting immunoglobulin variable exons.

This study shows that splice-switching ASOs targeting V exons in myeloma cells induce selective plasma cell clone death via ER stress and apoptosis.

Pyruvate from bone marrow mesenchymal stem cells supports myeloma redox homeostasis and anabolism

This study shows that pyruvate from bone marrow mesenchymal stem cells supports myeloma cell redox homeostasis and anabolism through MCT-1/2 transporters.

Genetic Ethnicity and Hypertension Epistatic Interaction Underlying Racial Disparities in US Multiple Myeloma Susceptibility

The paper identifies an epistatic interaction between genetic ethnicity and hypertension that explains racial disparities in multiple myeloma risk among Black and mixed-ancestry individuals.

Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma

This study identifies molecular mechanisms of carfilzomib resistance in multiple myeloma using multi-omics data from cell lines and patient samples, revealing potential drug combinations to overcome resistance.

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies

The paper shows that genomic antigen escape mechanisms in multiple myeloma occur during CAR-T/TCE treatment, not pre-existing, and emerge after one year of therapy.

The SAGA acetyltransferase module is required for the maintenance of MAF and MYC oncogenic gene expression programs in multiple myeloma

The paper identifies ADA2B's role in maintaining oncogenic gene expression programs in multiple myeloma through epigenetic mechanisms.

MyeloDB: A multi-omics resource for Multiple Myeloma

MyeloDB is a multi-omics database for multiple myeloma that integrates gene expression, methylation, CRISPR screens, and drug sensitivity data to identify novel drug targets.